What you missed at our Breakthrough Summit East!
Good evening and happy Sunday! We at STAT had an incredible time in NYC for our STAT Breakthrough East Summit. We discussed gene therapies, pharma R&D, biotech, patient advocacy, racial health disparities, and more. We want to share with you all the news that came out of the event that this week’s newsletter is titled (by Alexander) “Weekly Update (Summit Version).”?
So, let’s hop to it …?
Why did Editas get outpaced by its peers?
When biotech companies started forming to capitalize on the genome-editing technology CRISPR, Editas Medicine seemed like the pacesetter, especially after it scooped up pioneering scientist Feng Zhang of the Broad Institute as one of its founders. After 10 years now, why has the company been outperformed by CRISPR Therapeutics , Vertex Pharmaceuticals , and Intellia Therapeutics, Inc. ?
During our Breakthrough Summit, Zhang offered his perspective .?
Challenges of getting CRISPR treatments to patients
“Science is not the limiting factor anymore.” — Julia Vitarello , founder and CEO of Mila’s Miracle Foundation
In order for gene-editing tool CRISPR to reach its full potential, researchers and disease advocates say they’ll have to solve a thorny problem: connecting patients suffering from devastating diseases with therapies that could help them.
Experts at the Breakthrough Summit offered their solutions to this problem.?
领英推荐
Curing allergies: Regeneron’s plan for the future
Regeneron chief scientific officer George Yancopoulos outlined his company’s plan for curing allergies. Watch him explain it in his own words .
?
GLP-1s and addiction?
Top U.S. addiction researcher Nora Volkow called early data for GLP-1 medications like Ozempic and Wegovy to treat addiction “very, very, exciting” during our #STATBreakthrough Summit East. But she also criticized big pharma companies for neglecting a moral imperative to develop new addiction treatments. Read her full comments here .
STAT Madness on stage
What happens when our #STATBreakthrough Summit coincides with our #STATMadness tournament? You get Madness on stage! Four contestants presented their innovations in front of a panel of judges and event attendees cast their votes for the fan-favorite “STAT Madness All-Star.” Read and find out who took home the prize .
The future of drug development?
Drug development is becoming more of a sprint than a marathon, according to three biotech leaders speaking with Damian Garde at #STATBreakthrough Summit East.?
“We used to say, well, you may spend five years in the research phase, another five in development. Now I see a project that takes one year of research, from an idea to studies,” said Mikael Dolsten, chief scientific officer and president of Pfizer research and development.